Top

Current Hematologic Malignancy Reports

Published in:

01-02-2018 | T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor)

Immunologic Milieu of Mature T-Cell and NK-Cell Lymphomas—Implications for Therapy

Authors: Eric Tse, Yok-Lam Kwong

Published in: Current Hematologic Malignancy Reports | Issue 1/2018

Abstract

Purpose of the Review

T-cells and natural killer (NK) cells share the same ontogeny, and lymphomas derived from them are clinically diverse, occurring in nodal and extranodal sites. In addition to inherent properties of these lymphomas, their microenvironment also impacts on pathogenesis and response to therapy. An understanding of the milieu of T-cell and NK cell lymphomas has important implications on treatment.

Recent Findings

Components of the microenvironment include tumour-associated macrophages (TAM), non-neoplastic T-cells and B-cells, eosinophils, dendritic cells, endothelial cells and blood vessels. TAM typically undergoes M2 polarization, promoting angiogenesis and inhibiting anti-tumour cellular immunity. In lymphomas of follicular helper T-cell derivation, increased B-cell proliferation occurs, which may in turn enhance neoplastic T-cell growth. The expression of immune checkpoint ligands on TAM, dendritic cells or lymphoma cells induces an immunosuppressive environment conducive to neoplastic proliferation. Strategies against this complex cellular and immunologic microenvironment have shown promises. These include the use of signal transduction inhibitors, monoclonal antibodies against chemokines or non-neoplastic microenvironmental cells, immunomodulatory drugs and immune checkpoint blockade. As T-cell and NK cell lymphomas are highly heterogeneous, clinical trials to demonstrate efficacy of a given therapeutic approach requires careful design aiming at enriching patient populations who will best respond.

Summary

Targeting of the immunologic milieu in T-cell and NK-cell lymphomas offers exciting challenges and opportunities.

Sun JC, Lanier LL. NK cell development, homeostasis and function: parallels with CD8⁺ T cells. Nat Rev Immunol. 2011;11(10):645–57. https://doi.org/10.1038/nri3044.CrossRefPubMedPubMedCentral

Tse E, Kwong YL. Treatment algorithms for mature T-cell and natural killer-cell neoplasms. Future Oncol. 2011;7(9):1101–12. https://doi.org/10.2217/fon.11.84.CrossRefPubMed

Jaffe ES, Campo E, Harris NL, Pileri S, Stein H, Swerdlow SH. Introduction and overview of the classification of lymphoid neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, Siebert R, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2017. p. 190–8.

Tse E, Kwong YL. The diagnosis and management of NK/T-cell lymphomas. J Hematol Oncol. 2017;10(1):85. https://doi.org/10.1186/s13045-017-0452-9.CrossRefPubMedPubMedCentral

Li Z, Xia Y, Feng LN, Chen JR, Li HM, Cui J, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. Lancet Oncol. 2016;17(9):1240–7. https://doi.org/10.1016/S1470-2045(16)30148-6.CrossRefPubMed

Sonoda S, Li HC, Tajima K. Ethnoepidemiology of HTLV-1 related diseases: ethnic determinants of HTLV-1 susceptibility and its worldwide dispersal. Cancer Sci. 2011;102(2):295–301. https://doi.org/10.1111/j.1349-7006.2010.01820.x.CrossRefPubMed

Romanos J, van Diemen CC, Nolte IM, Trynka G, Zhernakova A, Fu J, et al. Analysis of HLA and non-HLA alleles can identify individuals at high risk for celiac disease. Gastroenterology. 2009;137(3):834–40. https://doi.org/10.1053/j.gastro.2009.05.040.CrossRefPubMed

Liu E, Lee HS, Aronsson CA, Hagopian WA, Koletzko S, Rewers MJ, et al. Risk of pediatric celiac disease according to HLA haplotype and country. N Engl J Med. 2014;371(1):42–9. https://doi.org/10.1056/NEJMoa1313977.CrossRefPubMedPubMedCentral

Leonard MM, Sapone A, Catassi C, Fasano A. Celiac disease and nonceliac gluten sensitivity: a review. JAMA. 2017;318(7):647–56. https://doi.org/10.1001/jama.2017.9730.CrossRefPubMed

10.

• Tse E, Kwong YL. T-cell lymphoma: Microenvironment-related biomarkers. Semin Cancer Biol. 2015;34:46–51. A comprehensive review of potential biomarkers for response to treatment based on the microenvironment in T-cell lymphomas.CrossRefPubMed

11.

Aras S, Zaidi MR. TAMeless traitors: macrophages in cancer progression and metastasis. Br J Cancer. 2017;117(11):1583–91. https://doi.org/10.1038/bjc.2017.356.CrossRefPubMedPubMedCentral

12.

Lu L, Barbi J, Pan F. The regulation of immune tolerance by FOXP3. Nat Rev Immunol. 2017;17(11):703–71711. https://doi.org/10.1038/nri.2017.75.CrossRefPubMedPubMedCentral

13.

Enokida T, Nishikawa H. Regulatory T cells, as a target in anticancer immunotherapy. Immunotherapy. 2017;9(8):623–7. https://doi.org/10.2217/imt-2017-0057.CrossRefPubMed

14.

• Gaulard P, de Leval L. The microenvironment in T-cell lymphomas: emerging themes. Semin Cancer Biol. 2014;24:49–60. a comprehensive review of the components of the microenvironment in T-cell lymphomas.CrossRefPubMed

15.

Choi YS, Kageyama R, Eto D, Escobar TC, Johnston RJ, Monticelli L, et al. ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. Immunity. 2011;34(6):932–46. https://doi.org/10.1016/j.immuni.2011.03.023.CrossRefPubMedPubMedCentral

16.

Kratochvill F, Neale G, Haverkamp JM, Van de Velde LA, Smith AM, Kawauchi D, et al. TNF counterbalances the emergence of M2 tumor macrophages. Cell Rep. 2015;12(11):1902–14. https://doi.org/10.1016/j.celrep.2015.08.033.CrossRefPubMedPubMedCentral

17.

Pals ST, de Gorter DJ, Spaargaren M. Lymphoma dissemination: the other face of lymphocyte homing. Blood. 2007;110(9):3102–11. https://doi.org/10.1182/blood-2007-05-075176.CrossRefPubMed

18.

Lemonnier F, Mak TW. Angioimmunoblastic T-cell lymphoma: more than a disease of T follicular helper cells. J Pathol. 2017;242(4):387–90. https://doi.org/10.1002/path.4920.CrossRefPubMed

19.

Schwartz FH, Cai Q, Fellmann E, Hartmann S, Mäyränpää MI, Karjalainen-Lindsberg ML, et al. TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma. J Pathol. 2017;242(2):129–33. https://doi.org/10.1002/path.4898.CrossRefPubMed

20.

•• Wang T, Feldman AL, Wada DA, Lu Y, Polk A, Briski R, et al. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood. 2014;123(19):3007–15. original observations of how gene expression profiles in T-cell lymphomas impact on microenvironmental changes and prognosis.CrossRefPubMedPubMedCentral

21.

Werner MT, Zhao C, Zhang Q, Wasik MA. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target. Blood. 2017;129(7):823–31. https://doi.org/10.1182/blood-2016-05-717793.CrossRefPubMed

22.

Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116(5):767–71. https://doi.org/10.1182/blood-2009-11-251926.CrossRefPubMedPubMedCentral

23.

Rubio-Gonzalez B, Zain J, Rosen ST, Querfeld C. Clinical manifestations and pathogenesis of cutaneous lymphomas: current status and future directions. Br J Haematol. 2017;176(1):16–36. https://doi.org/10.1111/bjh.14402.CrossRefPubMed

24.

• Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19(13):3462–73. original observations of how infection with Epstein Barr virus upregulates the expression of PDL1.CrossRefPubMedPubMedCentral

25.

Bi XW, Wang H, Zhang WW, Wang JH, Liu WJ, Xia ZJ, et al. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. J Hematol Oncol. 2016;9(1):109. https://doi.org/10.1186/s13045-016-0341-7.CrossRefPubMedPubMedCentral

26.

Nagato T, Ohkuri T, Ohara K, Hirata Y, Kishibe K, Komabayashi Y, et al. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. Cancer Immunol Immunother. 2017;66(7):877–90. https://doi.org/10.1007/s00262-017-1987-x.CrossRefPubMed

27.

Niino D, Komohara Y, Murayama T, Aoki R, Kimura Y, Hashikawa K, et al. Ratio of M2 macrophage expression is closely associated with poor prognosis for angioimmunoblastic T-cell lymphoma (AITL). Pathol Int. 2010;60(4):278–83. https://doi.org/10.1111/j.1440-1827.2010.02514.x.CrossRefPubMed

28.

Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel). 2014;6(3):1670–90. https://doi.org/10.3390/cancers6031670.CrossRef

29.

Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123(19):2915–23.CrossRefPubMedPubMedCentral

30.

Batlevi CL, Matsuki E, Brentjens RJ, Younes A. Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol. 2016;13(1):25–40. https://doi.org/10.1038/nrclinonc.2015.187.CrossRefPubMed

31.

Wu X, Schulte BC, Zhou Y, Haribhai D, Mackinnon AC, Plaza JA, et al. Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo. J Invest Dermatol. 2014;134(11):2814–22. https://doi.org/10.1038/jid.2014.206.CrossRefPubMed

32.

Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet. 2015;47(9):1011–9. https://doi.org/10.1038/ng.3356.CrossRefPubMedPubMedCentral

33.

Chen J, Zhang Y, Petrus MN, Xiao W, Nicolae A, Raffeld M, et al. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations. Proc Natl Acad Sci U S A. 2017;114(15):3975–80. https://doi.org/10.1073/pnas.1700682114.CrossRefPubMedPubMedCentral

34.

Delfau-Larue MH, de Leval L, Joly B, Plonquet A, Challine D, Parrens M, et al. Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. Haematologica. 2012;97(10):1594–602. https://doi.org/10.3324/haematol.2011.061507.CrossRefPubMedPubMedCentral

35.

Kater AP, Tonino SH, Egle A, Ramsay AG. How does lenalidomide target the chronic lymphocytic leukemia microenvironment? Blood. 2014;124(14):2184–9. https://doi.org/10.1182/blood-2014-05-578286.CrossRefPubMed

36.

Toumishey E, Prasad A, Dueck G, Chua N, Finch D, Johnston J, et al. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer. 2015;121(5):716–23. https://doi.org/10.1002/cncr.29103.CrossRefPubMed

37.

Querfeld C, Rosen ST, Guitart J, Duvic M, Kim YH, Dusza SW, et al. Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome. Blood. 2014;123(8):1159–66. https://doi.org/10.1182/blood-2013-09-525915.CrossRefPubMed

38.

Bruns I, Fox F, Reinecke P, Kobbe G, Kronenwett R, Jung G, et al. Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia. 2005;19(11):1993–5. https://doi.org/10.1038/sj.leu.2403936.CrossRefPubMed

39.

Aguiar Bujanda D. Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab. Ann Oncol. 2008;19(2):396–7. https://doi.org/10.1093/annonc/mdm579.CrossRefPubMed

40.

Ganjoo K, Hong F, Horning SJ, Gascoyne RD, Natkunam Y, Swinnen LJ, et al. Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leuk Lymphoma. 2014;55(4):768–72. https://doi.org/10.3109/10428194.2013.816700.CrossRefPubMed

41.

Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32(11):1157–63. https://doi.org/10.1200/JCO.2013.52.0924.CrossRefPubMed

42.

Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015;125(12):1883–9. https://doi.org/10.1182/blood-2014-09-600924.CrossRefPubMedPubMedCentral

43.

Sugiyama D, Nishikawa H, Maeda Y, Nishioka M, Tanemura A, Katayama I, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A. 2013;110(44):17945–50. https://doi.org/10.1073/pnas.1316796110.CrossRefPubMedPubMedCentral

44.

Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698–704. https://doi.org/10.1200/JCO.2015.65.9789.CrossRefPubMedPubMedCentral

45.

Chan TSY, Li J, Loong F, Khong PL, Tse E, Kwong YL. PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase: efficacy and safety. Ann Hematol. 2017.

46.

Wartewig T, Kurgyis Z, Keppler S, Pechloff K, Hameister E, Öllinger R, et al. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature. 2017;552(7683):121–5. https://doi.org/10.1038/nature24649.PubMed

47.

• Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017;129(17):2437–42. original observations of the high efficacy of PD1 blockade in NK-cell lymphoma.CrossRefPubMed

Title: Immunologic Milieu of Mature T-Cell and NK-Cell Lymphomas—Implications for Therapy
Authors: Eric Tse
Yok-Lam Kwong
Publication date: 01-02-2018
Publisher: Springer US
Published in: Current Hematologic Malignancy Reports / Issue 1/2018
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI: https://doi.org/10.1007/s11899-018-0437-y

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Immunologic Milieu of Mature T-Cell and NK-Cell Lymphomas—Implications for Therapy

Abstract

Purpose of the Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose of the Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 1/2018

Twitter Use in the Hematopoietic Cell Transplantation Community

Biomarkers in Graft-Versus-Host Disease: from Prediction and Diagnosis to Insights into Complex Graft/Host Interactions

The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL)

Updates of Peripheral T Cell Lymphomas Based on the 2017 WHO Classification

NK/T Cell Lymphoma: Updates in Therapy

Central Nervous System Involvement in Peripheral T Cell Lymphoma

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page